Treanda

Type: Product
Name: Treanda
First reported Oct 19 2014 - Updated Oct 19 2014 - 1 reports

Welsh Cancer Plan: health boards 'must be held to account'

Local Health Boards in Wales must be held to account for delivering the government’s Cancer Delivery Plan, politicians have urged, and they also warn that, without “stronger national leadership,” the Plan’s goals may not be met. The Minister for Health ... [Published Pharma Times - Oct 19 2014]
First reported Oct 06 2014 - Updated Oct 06 2014 - 1 reports

Court Report - October 2014

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases .Shire LLC v. Amerigen Pharmaceuticals Ltd.1:14-cv-06095; filed October , 2014 in the District Court of New JerseyInfringement of U.S. Patent Nos. RE42,096 ... [Published JD Supra - Oct 06 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Gilead’s Zydelig And Johnson and Johnson-Pharmacyclic’s Imbruvica Fighting To Lead Anti-Cancer Drug Race

Gilead and J&J are going head-to-head with their drugs Zydelig and Imbruvica, used to treat various indications related to cancer. Despite Gilead‘s lower pricing it still needs to cope with black box warnings associated with ZydeligPage 1 of 3Click Ticker ... [Published Bidness Etc - Sep 22 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Allogeneic Conditioning Regimen Reduces Myelosuppression, Graft-vs-Host Disease in Lymphocytic Leukemia/Lymphoma

By Charlotte BathSeptember 15, 2014, Volume 5, Issue 15The combination of bendamustine (Treanda), fludarabine, and rituximab (Rituxan), or BFR, was shown to be safe and effective conditioning for patients with relapsed chronic lymphocytic leukemia/lymphoma ... [Published The ASCO Post - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Court Report -- Part III: September 2014

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases .Forest Laboratories LLC et al. v. Sigmapharm Laboratories LLC1:14-cv-01119; filed September 3, 2014 in the District Court of Delaware• Plaintiffs:  Forest ... [Published JD Supra - Sep 12 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

Breckenridge Pharmaceutical, Inc. Announces Paragraph IV ANDA Litigation with Cephalon, Inc. for its ANDA Bendamustine HCl Powder for IV (Treanda®)

BOCA RATON, Fla., June 23, 2014 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has filed an ANDA with a Paragraph IV certification for bendamustine hydrochloride powder for IV (infusion), 25 mg/vial and 100 mg/vial, a generic ... [Published PR Newswire: Policy & Public Interest - Jun 23 2014]
First reported May 05 2014 - Updated May 05 2014 - 1 reports

Court Report

By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Cephalon Inc. v. Uman Pharma Inc. 1:14-cv-00568; filed April 30, 2014 in the District Court of Delaware Infringement of U.S. Patent Nos. ... [Published Patent Docs - May 05 2014]

Quotes

Infringement of U S Patent Nos. 6,028,222 ( "Stable Liquid Paracetamol Compositions, and Method for Preparing the Same" issued February 22, 2000) and 6,992,218 ("Method for Obtaining Aqueous Formulations of Oxidation-Sensitive Active Principles," issued January 31, 2006)...
Infringement of U S Patent No. 6,015,577 ( "Pharmaceutical Compositions Containing Dipyridamole or Mopidamol and Acetylsalicylic Acid or the Physiologically Acceptable Salts Thereof, Processes for Preparing Them and Their Use in Treating Clot Formation" issued January 18, 2000) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Boehringer's...

More Content

All (8) | News (6) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Welsh Cancer Plan: health boards 'must be held ... [Published Pharma Times - Oct 19 2014]
Court Report - October 2014 [Published JD Supra - Oct 06 2014]
Gilead’s Zydelig And Johnson and Johnson-Pharma... [Published Bidness Etc - Sep 22 2014]
Allogeneic Conditioning Regimen Reduces Myelosu... [Published The ASCO Post - Sep 15 2014]
Court Report -- Part III: September 2014 [Published JD Supra - Sep 12 2014]
Breckenridge Pharmaceutical, Inc. Announces Par... [Published PR Newswire: Policy & Public Interest - Jun 23 2014]
Court Report [Published Patent Docs - May 05 2014]
Cephalon files suit against Actavis on generic ... [Published PharmaBiz - Feb 06 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Breckenridge Pharmaceutical, Inc. Announces Par... [Published PR Newswire: Policy & Public Interest - Jun 23 2014]
BOCA RATON, Fla., June 23, 2014 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has filed an ANDA with a Paragraph IV certification for bendamustine hydrochloride powder for IV (infusion), 25 mg/vial and 100 mg/vial, a generic ...
Court Report [Published Patent Docs - May 05 2014]
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Cephalon Inc. v. Uman Pharma Inc. 1:14-cv-00568; filed April 30, 2014 in the District Court of Delaware Infringement of U.S. Patent Nos. ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.